Pfizer Inc. (PFE) stock currently trades at roughly half the high it closed at in December 2021. Many shareholders still ...

Pfizer has delivered a solid 1 year return, yet the question many investors are circling is whether that share price now ...

Pfizer Inc PFE shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after ...

A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right ...

Pfizer just got a reality check from one of Wall Street’s biggest banks, and the timing could not be more awkward heading into the second half of the year. HSBC downgraded Pfizer to Hold from Buy on ...

Jefferies' USD 36.00 target is materially above Pfizer's USD 29.73 New York Stock Exchange quote, while the latest quarterly ...

The stock has outperformed the market this year, and it still looks heavily undervalued.

Pfizer has quietly become one of healthcare’s better price stories in 2026. Shares are up 18.58% year to date and 15.08% over the past month, closing at $28.07, essentially at the 52-week high of ...

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the ...